cancer Clinical Trials drug development Surgery

Neoadjuvant Combination Checkpoint Blockade Trial Yields High Response Rates for Patients with High-Risk Stage 3 Melanoma

Combination checkpoint blockade before surgery (neoadjuvant therapy) produced a high response rate among patients with high-risk stage 3 melanoma, with nearly half having no sign of disease at surgery, but a high incidence of side effects caused the trial to be closed early. The phase II study was led by researchers at The University of Texas MD Anderson Cancer Center. Results of the study, the first randomized neoadjuvant clinical trial
Biotechnology cancer Immunotherapies rare diseases

Smart Bomb Virus Shows Promise as Brain Tumor Immunotherapy

A common cold virus engineered to attack the most common and deadly of brain tumors allowed 20 percent of patients with recurrent glioblastoma to live for three years or longer, researchers from The University of Texas MD Anderson Cancer Center report on a phase I clinical trial in the Journal of Clinical Oncology. The altered adenovirus, called Delta-24-RGD or DNX-2401, was injected one time directly into the tumors of 25